DDInter1351 DDInter1435
Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Osilodrostat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Osilodrostat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Osilodrostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zileuton
Osilodrostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elagolix
Osilodrostat {u} may lead to a major life threatening interaction when taken with {v} Tizanidine
Osilodrostat {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Osilodrostat may lead to a major life threatening interaction when taken with Tizanidine
Osilodrostat may lead to a major life threatening interaction when taken with Ivosidenib